Skip to content

2029 at other companies

Solventum logo
SolventumSOLV
CONMED logo
CONMEDCNMD

Other financials

Income statement

See full
Revenue$27.8M+18.6%
Gross profit$25.9M+19.8%
Operating income$2.6M+221%
Net income$459.0K+113%
EPS (diluted)$0.05+112%

Balance sheet

See full
Cash & equivalents$13.6M-34.3%
Total debt$48.4M+8.2%
Total equity$7.0M-80.8%
Total assets$69.3M-28.1%

Cash flow

See full
Operating cash flow-$2.5M-23.3%
CapEx$43.8K-97.5%
Free cash flow-$2.5M+32.6%

Valuation

See full
Market cap$216.18M-9.7%
Enterprise value$250.95M-6.5%
P/S-0.5×

Profitability

See full
Gross margin92.9%+1.8pp
Operating margin6.1%+5.1pp
Net margin-31.2%-93.4pp
FCF margin-9.8%-3.5pp

Returns & leverage

See full
Return on equity-153.7%-199pp
Debt / equity6.9×+5.7×
Current ratio2.3×-0.5×

Where this comes from

Reported directly by Sanara MedTech Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sanara MedTech Inc.'s 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sanara MedTech Inc.'s 2029?
Sanara MedTech Inc. (SMTI) reported 2029 of $47.11M in Q1 2026.